GNAI1

Chr 7AD

G protein subunit alpha i1

Also known as: Gi, HG1B, NEDHISB

Guanine nucleotide binding proteins are heterotrimeric signal-transducing molecules consisting of alpha, beta, and gamma subunits. The alpha subunit binds guanine nucleotide, can hydrolyze GTP, and can interact with other proteins. The protein encoded by this gene represents the alpha subunit of an inhibitory complex. The encoded protein is part of a complex that responds to beta-adrenergic signals by inhibiting adenylate cyclase. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.381 OMIM phenotype
Clinical SummaryGNAI1
🧬
Gene-Disease Validity (ClinGen)
complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.91). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
20 unique Pathogenic / Likely Pathogenic· 94 VUS of 149 total submissions
📖
GeneReview available — GNAI1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.38LOEUF
pLI 0.911
Z-score 3.32
OE 0.12 (0.050.38)
Highly constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
2.63Z-score
OE missense 0.45 (0.380.54)
83 obs / 183.1 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.12 (0.050.38)
00.351.4
Missense OE?0.45 (0.380.54)
00.61.4
Synonymous OE?1.34
01.21.6
LoF obs/exp: 2 / 16.6Missense obs/exp: 83 / 183.1Syn Z: -2.05
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
moderateGNAI1-related neurodevelopmental disorder with hypotonia, impaired speech, and behavioural abnormalitiesOTHERAD

This gene — mechanism propensity

DN
0.4983th %ile
GOF
0.6639th %ile
LOF
0.48top 25%

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 95% of P/LP are missense
LOFLOEUF 0.38

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

149 submitted variants in ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic14
VUS94
Likely Benign14
Benign6
Conflicting3
6
Pathogenic
14
Likely Pathogenic
94
VUS
14
Likely Benign
6
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
6
0
0
6
Likely Pathogenic
0
13
1
0
14
VUS
14
76
4
0
94
Likely Benign
0
5
3
6
14
Benign
0
0
1
5
6
Conflicting
3
Total14100911137

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

14 pathogenic / likely-pathogenic (of 23) ClinVar copy-number / structural variants overlap GNAI1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

GNAI1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →